Clinical Trials Logo

Gout Flares clinical trials

View clinical trials related to Gout Flares.

Filter by:
  • None
  • Page 1

NCT ID: NCT06444867 Not yet recruiting - Joint Pain Clinical Trials

A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968

Start date: June 2024
Phase: Phase 1
Study type: Interventional

The main objective of the study is to evaluate the effect on pain of a single, subcutaneous (SC) dose of LEO 158968 in participants with gout flares.

NCT ID: NCT01712204 Completed - Gout Flares Clinical Trials

A Proof-of-Concept Study of AC-201 to Prevent Gout Flares

Start date: January 2013
Phase: Phase 2
Study type: Interventional

Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis. The efficacy of IL-1β blockade in the prophylaxis of gouty flares during initiation of ULT has been validated in multiple trials of IL-1β inhibitor therapies. Therefore, it is believed that IL-1β is a relevant therapeutic target for gout flares. AC-201 is an IL-1β modulator indicated for the treatment of osteoarthritis with good safety record and very few contraindications to the co-morbidities commonly among gout patients. AC-201 has also been demonstrated to have uric acid-lowering effects in clinical trials. The favorable product profile of AC-201 overall provides a strong rationale for investigating its clinical utility as prophylaxis against flares when initiating ULT.